Temazepam
NDC 40032-121
Product Information
Temazepam is a ANDA-approved product labeled by Novel Laboratories, Inc.. This medication is used to treat a certain sleep problem (insomnia). It is supplied as a white product. This product entry covers the primary NDC 40032-121 and 2 associated package configurations. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
PINK (C48328 - OPAQUE CAP)
BLUE (C48333 - OPAQUE CAP)
7;5MG;NOVEL120
15MG;NOVEL121
Code Structure Chart
Product Details
What is NDC 40032-121?
What are the uses of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- TEMAZEPAM (UNII: CHB1QD2QSS)
- TEMAZEPAM (UNII: CHB1QD2QSS) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- STARCH, CORN (UNII: O8232NY3SJ)
- ANHYDROUS LACTOSE (UNII: 3SY5LH9PMK)
- MAGNESIUM STEARATE (UNII: 70097M6I30)
- SODIUM LAURYL SULFATE (UNII: 368GB5141J)
- FD&C RED NO. 40 (UNII: WZB9127XOA)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- ALCOHOL (UNII: 3K9958V90M)
- ISOPROPYL ALCOHOL (UNII: ND2M416302)
- BUTYL ALCOHOL (UNII: 8PJ61P6TS3)
- SHELLAC (UNII: 46N107B71O)
- POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- FERROSOFERRIC OXIDE (UNII: XM0M87F357)
- FD&C BLUE NO. 1 (UNII: H3R47K3TBD)
- FD&C YELLOW NO. 6 (UNII: H77VEI93A8)
- GELATIN (UNII: 2G86QN327L)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 198241 - temazepam 15 MG Oral Capsule
- RxCUI: 198242 - temazepam 30 MG Oral Capsule
- RxCUI: 198243 - temazepam 7.5 MG Oral Capsule
- RxCUI: 485489 - temazepam 22.5 MG Oral Capsule
* Please review the full disclaimer at the bottom of this page.